Heart Failure, Congestive Clinical Trial
Official title:
The Effect of Intramyocardial Injection of Immunoselected Bone Marrow Cells on Myocardial Function in LVAD Bridge to Transplant Patients
Heart failure is a condition in which the heart is unable to pump enough blood to the body's other organs. A heart transplant may be necessary for some individuals with end-stage heart failure. Left ventricular assist devices (LVADs) can assist the heart in pumping blood, and are commonly used until a donor heart becomes available. Bone marrow cells injected into the heart may improve heart function and may lead to earlier LVAD removal. The purpose of this study is to evaluate the safety and effectiveness of injected bone marrow cells in improving heart function in individuals with LVADs who are awaiting heart transplants.
Congestive heart failure affects 5 million people in the United States, and over 60,000 are
diagnosed with end-stage heart failure. Treatment options for these individuals are extremely
limited. Because of a limited supply of donor organs, fewer than 3,000 people receive heart
transplants each year. LVADs are battery-operated devices that can act as a temporary
solution until a donor heart becomes available. Upon being surgically implanted into a
weakened heart, the LVAD mechanically pumps blood from the heart to the rest of the body.
There are, however, serious risks associated with LVADs, including infection, blood clots,
and stroke. Early removal of the LVAD may be possible by injecting stem cells to regenerate
new heart cells and improve heart function. The purpose of this study is to compare the
safety and effectiveness of two types of bone marrow cells -- bone marrow mononuclear cells
(BMCs) and immunoselected CD34+ hematopoietic stem cells -- in improving heart function in
individuals with end-stage heart failure.
This study will enroll individuals undergoing surgery to receive an LVAD. Participants will
be randomly assigned to one of following three groups:
Group 1 (n=30): participants will undergo intramyocardial injection of bone marrow
mononuclear cells (BMCs) during LVAD implantation
Group 2 (n=30): participants will undergo intramyocardial injection of immunoselected CD34+
hematopoietic stem cells during LVAD implantation
Group 3 (n=15): participants will undergo LVAD implantation
Prior to LVAD implantation, participants in Groups 1 and 2 will have a sample of bone marrow
removed. Following LVAD implantation, study visits will occur at Days 45 and 90, and then
every 60 days thereafter until participants receive a heart transplant. At each visit,
participants will undergo a LVAD wean procedure, during which the mechanical pump of the LVAD
will be gradually turned off, and the LVAD will be operated with a hand pump. The length of
time that a participant tolerates the wean procedure will be evaluated. Heart size and
function, blood flow, and nerve function will also be assessed. Some participants will
undergo a 6-minute walk test. At the time of heart transplant surgery, the LVAD will be
removed, and heart cell regeneration and heart function will be evaluated.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
| Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
| Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
| Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
| Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
| Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
| Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
| Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
| Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
| Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
| Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
| Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
| Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
| Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
| Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
| Completed |
NCT02772068 -
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
|
Early Phase 1 | |
| Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
| Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 | |
| Completed |
NCT00520806 -
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
|
Phase 2/Phase 3 |